PROMIS
-
ADHD, Autism, bumetanide, Drugs, epilepsy, neurodevelopmental disorders, PROMIS, PROMset, Psychiatry, sensory reactivity, single-case experimental design, tuberous sclerosis complexBumetanide PROMset Study: 83% Improved in 1 Sensory-Related Domain
A 2026 medRxiv preprint using parent-cocreated sensory-related outcome measures found that 83%…
